Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next?

Shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) rose 0.4% during mid-day trading on Monday . The company traded as high as $5.95 and last traded at $5.72. Approximately 17,352 shares were traded during trading, a decline of 64% from the average daily volume of 47,896 shares. The stock had previously closed at $5.70.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cadrenal Therapeutics has a consensus rating of “Hold” and a consensus price target of $32.00.

Cadrenal Therapeutics Trading Up 0.4%

The company has a market capitalization of $13.38 million, a PE ratio of -0.71 and a beta of 1.18. The stock’s 50-day moving average is $7.90 and its two-hundred day moving average is $10.87.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its earnings results on Monday, November 10th. The company reported ($1.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.24. On average, equities research analysts forecast that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 9,933 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total value of $69,233.01. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 26.09% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics in the 3rd quarter worth about $103,000. Finally, Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics during the third quarter worth approximately $274,000. 7.92% of the stock is currently owned by institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.